All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your ALL Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from Servier. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
FELIX trial: MRD-negative remission and clinical outcomes in R/R B-ALL treated with obe-cel
Bookmark this article
|
Obecabtagene autoleucel (obe-cel) is an autologous, anti-CD19 CAR T-cell therapy that was approved by the U.S. FDA for the treatment of adults with R/R B-ALL based on promising outcomes from the FELIX trial (NCT04404660). FELIX is a phase I/II multicenter, single-arm study evaluating the safety and efficacy of obe-cel in adult patients with R/R B-ALL (N = 127 infused). The ALL hub previously reported the efficacy and safety outcomes and key results from this trial. During the 66th ASH Annual Meeting and Exposition, Jabbour presented an analysis of the correlation between depth of MRD-negative remission and clinical outcomes in patients with R/R B-ALL treated with obe-cel in the FELIX trial.1 |
| Key learnings |
| 84% of responders achieved MRD-negative remission (<10⁻⁶ leukemic cells). The median time to best MRD response was 1 month, and depth of MRD-negative remission was associated with better clinical outcomes. |
| With a median follow-up of 21.5 months, patients who achieved MRD <10⁻⁶ had significantly better EFS than those with higher ≥10⁻4 MRD, at 17.9 months vs 4.5 months, respectively. |
| MRD-negative remission was achieved across all tumor burden subgroups. Lower tumor burden at lymphodepletion (BM blast <5% vs >75%) correlated with higher MRD-negativity rates (90% vs 72.2%), EFS benefits (NE vs 11.9 months), and OS benefits (NE vs 17.1 months). |
| The results demonstrated that obe-cel induces a high incidence of MRD-negative remission (<10⁻⁶), predicting better clinical outcomes and supporting its use in adult patients with R/R B-ALL. |
Abbreviations: B-ALL, B-cell acute lymphoblastic leukemia; EFS, event-free survival; FDA, U.S. Food and Drug Administration; MRD, minimal residual disease; NE, not estimable; OS, overall survival; R/R, relapsed and refractory.
- Jabbour E. Obecabtagene autoleucel (obe-cel) for adult relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL): Deep molecular remission may predict better outcomes. Oral Abstract #963. Presented at: 66th ASH Annual Meeting and Exposition; Dec 7–10, 2024; San Diego, US.
Your opinion matters
21 votes - 86 days left ...
Related articles
Newsletter
Subscribe to get the best content related to ALL delivered to your inbox